Compare American Water Works Company Inc (AWK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs Sanofi SA — how do they compare? American Water Works Company Inc trades at $135.82 (market cap $26.92B), while Sanofi SA trades at $43.65 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 3.9× American Water Works Company Inc's market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| AWK | SNY | |
|---|---|---|
Market Cap | $26.92B | $104.57B |
Sector | Utilities | Health |
52-Week High | $146.20 | $52.34 |
52-Week Low | $121.13 | $41.33 |
Enterprise Value | $42.78B | $124.48B |
Dividend Yield | 2.64% | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AWK trades at $135.31, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $1.61, beating estimates, while Q1 and Q4 2025 missed. Revenue grew to $5.14B in 2025 with a 21.35% net margin. Analyst consensus is mixed with 14 Buy, 14 Hold, and 2 Sell ratings, targeting $139.83. Recent news highlights operational excellence awards and customer base expansion through acquisitions.
Outlook remains stable with consistent dividend payments and guided EPS growth. Risks include rising debt levels and regulatory pressures. The stock offers steady income and moderate growth potential, but investors should monitor execution on earnings targets and capital expenditure efficiency.
SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.
SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
